The results of two independent trials suggest a role for the prophylactic use of angiotensin converting enzyme inhibitors or beta blockers in patients receiving an anthracycline-based regimen for HER2-positive or HER2-negative breast cancer.
ACC 2018; Orlando, Florida, USA, J Am Coll Cardiol 2018; Advance online publication
An analysis of the Surveillance, Epidemiology, and End Results database has found racial differences in age at breast cancer diagnosis, indicating that the current age-based US Preventive Services Task Force guidelines may lead to underscreening in women of ethnic minorities.
The efficacy of aromatase inhibition is comparable regardless of whether the agents are taken upfront for 5 years or for 3 years following 2 years of tamoxifen in postmenopausal women with hormone receptor-positive, early-stage breast cancer, researchers report.
Older women with metastatic, HER2-positive breast cancer derive a progression-free survival benefit from the addition of metronomic chemotherapy to the anti-HER2 agents pertuzumab and trastuzumab, indicate results from the EORTC 75111-10114 trial.
Here we provide top-line summaries of results from three phase III breast cancer trials, evaluating nab-paclitaxel and a trastuzumab biosimilar in the nonmetastatic HER2-negative and -positive settings, respectively, and quality of life with the addition of palbociclib in the advanced or metastatic setting.
The final analysis of the CALOR trial confirms the disease-free survival benefit of adjuvant chemotherapy for breast cancer patients with resected isolated locoregional recurrences that are estrogen receptor-negative and rules out its use in the ER-positive scenario.